NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate

MT Newswires Live

2025/02/12

NKGen Biotech (NKGN) shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.

The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.

NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.

Price: 0.47, Change: +0.09, Percent Change: +24.01

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2510430690"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510430690\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510430690?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510430690","market":"nz","top_or_hot":-1,"title":"NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> NKGen Biotech (NKGN) shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.</p><p>The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.</p><p>NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.</p><p>Price: 0.47, Change: +0.09, Percent Change: +24.01</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-12 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> NKGen Biotech (NKGN) shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.</p><p>The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.</p><p>NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.</p><p>Price: 0.47, Change: +0.09, Percent Change: +24.01</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510430690","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510430690","pubTimestamp":1739373869,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NKGen Biotech  shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.Price: 0.47, Change: +0.09, Percent Change: +24.01","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NKGN":"NKGen Biotech Inc.","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","BK4104":"贸易公司与经销商","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4588":"碎股","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","FAST":"快扣"},"translate_title":"FDA授予阿尔茨海默病候选药物快速通道地位后，NKGen Biotech股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FAST":1,"NKGN":0.9},"content_text":"NKGen Biotech (NKGN) shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.Price: 0.47, Change: +0.09, Percent Change: +24.01","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}